SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention amid volatile pre-earnings trading, with traders weighing expectations for Q3 results and possible guidance against a broader selloff in AI and growth stocks tied to inflation and interest-rate concerns. Bulls point to data-center power demand and deals involving AEP, Google and Oracle, while bears question the stocks valuation and warn of further downside or a sell-the-news reaction.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformanceeven as Bitcoin has held up or reboundedare driving discussion. Traders largely blame skepticism about the AI/data-center pivot without signed tenant leases and concerns over finances and management, while some see the decline as overdone and anticipate a rebound if Bitcoin strengthens or a deal emerges.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts Maia 300 custom AI chip and plans to expand its use are drawing attention, with traders weighing the potential for lower AI computing costs and reduced reliance on outside suppliers. Optimism about Azure and AI monetization competes with concerns that heavy infrastructure spending may not deliver sufficient returns.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet shares are under pressure amid a broader tech selloff and concerns about macro conditions, with traders debating whether the weakness reflects market-wide moves or company-specific worries about AI competition and spending. The community is split between dip-buyers watching technical support and bears focused on persistent selling, with upcoming earnings seen as a key test for cloud growth and AI execution.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVies run to fresh highs is drawing attention amid a rotation into defensive healthcare stocks, with traders highlighting breakout momentum while some caution that the shares look overextended. Positive Crohns disease and oncology pipeline updates are also part of the discussion, alongside speculation about AbbVie as a potential biotech acquirer.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, with traders celebrating the move and watching for a breakout. No confirmed catalyst dominates; speculation about Flexa adoption and ties to ANVL competes with skepticism that the rally may fade like prior pump-and-dump moves.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after a steep pullback despite two recent Q3 revenue outlook increases, which the company attributed to royalties from its Vertical Power Delivery technology licensing. Traders are divided between buying the weakness ahead of the earnings report and worrying that the selloff reflects fading momentum, profit-taking, or broader pressure on tech stocks.

Aventus Network

AVT is drawing attention amid a volatile rebound, with traders watching rising activity and a thin order book for signs of a breakout. Aventus Clouds decentralized-compute updates add to the bullish narrative, while others point to selling pressure, concentrated ownership, and supply concerns as risks to sustaining momentum.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers steady climb toward a 52-week high has traders focused on whether it can break through the psychologically important $30 level; bullish posts point to call activity, pipeline progress and demand for defensive, dividend-paying stocks, while others expect resistance or a range-bound move. No single catalyst dominates the discussion.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data on lifileucel is driving attention, especially the mature frontline melanoma results with pembrolizumab and preliminary activity in sarcoma. Many traders view the melanoma response and durability findings as supportive of expansion potential, while others note the small cohorts and that the results do not establish success in the still-blinded Phase 3 TILVANCE-301 trial.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Womens Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA, a hormone-free, copper intrauterine...

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA (tapinarof) cream, 1% will be on display at the 2026 Fall...

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Womens Healths supplemental New Drug Application (sNDA) for MIUDELLA...

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA (copper intrauterine system) Risk Evaluation and Mitigation Strategy (REMS) Program is now open for enrollment at...

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon (OGN) Lags Q2 Earnings Estimates

Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

OGN Organon & Co.

Fundamentals

Latest OGN News